CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced business updates and financial results for the fourth quarter and full-year 2020.